Short Interest in Cellebrite DI Ltd. (NASDAQ:CLBT) Expands By 13.6%

Cellebrite DI Ltd. (NASDAQ:CLBTGet Free Report) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,170,000 shares, an increase of 13.6% from the December 31st total of 1,030,000 shares. Based on an average daily volume of 1,310,000 shares, the days-to-cover ratio is presently 0.9 days. Approximately 1.4% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. JPMorgan Chase & Co. raised their price objective on Cellebrite DI from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Monday, December 16th. Craig Hallum raised their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, Needham & Company LLC upped their price objective on shares of Cellebrite DI from $21.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday, January 22nd. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $21.57.

View Our Latest Research Report on CLBT

Hedge Funds Weigh In On Cellebrite DI

Hedge funds have recently bought and sold shares of the business. Sei Investments Co. raised its position in Cellebrite DI by 16.9% during the second quarter. Sei Investments Co. now owns 141,644 shares of the company’s stock worth $1,693,000 after acquiring an additional 20,478 shares during the period. Point72 Asia Singapore Pte. Ltd. raised its position in shares of Cellebrite DI by 59.6% during the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock worth $33,000 after purchasing an additional 1,017 shares during the last quarter. Strategic Advisors LLC purchased a new position in Cellebrite DI in the 3rd quarter valued at about $474,000. Juncture Wealth Strategies LLC boosted its holdings in Cellebrite DI by 42.2% in the 3rd quarter. Juncture Wealth Strategies LLC now owns 59,498 shares of the company’s stock worth $1,002,000 after buying an additional 17,652 shares during the last quarter. Finally, Pathway Financial Advisers LLC increased its stake in Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock worth $74,000 after buying an additional 4,118 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Up 2.5 %

Shares of NASDAQ CLBT traded up $0.60 during midday trading on Monday, reaching $24.64. 1,404,701 shares of the stock were exchanged, compared to its average volume of 1,526,417. The firm has a 50-day simple moving average of $21.77 and a two-hundred day simple moving average of $18.46. Cellebrite DI has a twelve month low of $8.91 and a twelve month high of $24.89. The firm has a market cap of $5.07 billion, a price-to-earnings ratio of -15.89, a PEG ratio of 3.55 and a beta of 1.47.

Cellebrite DI (NASDAQ:CLBTGet Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The company had revenue of $106.90 million during the quarter, compared to analysts’ expectations of $102.06 million. During the same quarter in the previous year, the company earned $0.09 earnings per share. The firm’s revenue for the quarter was up 27.0% on a year-over-year basis. Research analysts expect that Cellebrite DI will post 0.32 EPS for the current fiscal year.

About Cellebrite DI

(Get Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Read More

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.